Malaria vaccine trial endpoints - Bridging the gaps between trial design, public health and the next generation of vaccines

Parasite Immunology

Volumn 31, Issue 9, 2009, Pages 574-581

  O'Meara, W P ^a   Lang, T ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trial; Efficacy; Endpoint; Malaria; Vaccine

Indexed keywords

MALARIA VACCINE;

CHILL; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; FEVER; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; IMMUNITY; IMMUNIZATION; INCIDENCE; LONG TERM CARE; MALARIA; MORTALITY; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MALARIA; MALARIA VACCINES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 68949084886     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01144.x     Document Type: Review

References (49)

1. Greenwood B. Interpreting vaccine efficacy. Clin Infect Dis 2005 40 : 1519 1520.
2. Lang T, Hughes D, Kanyok T, et al. Beyond registration - measuring the public-health potential of new treatments for malaria in Africa. Lancet Infect Dis 2006 6 : 46 52.
3. Deen JL Clemens JD. Issues in the design and implementation of vaccine trials in less developed countries. Nat Rev Drug Discov 2006 5 : 932 940.
4. MVAC. Malaria Vaccine Technology Roadmap: WHO Initiative for Vaccine Research. MVAC, 2006.
5. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008 359 : 2521 2532.
6. Halloran ME, Haber M Longini IM. Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992 136 : 328 343.
7. Alonso PL, Smith T, Schellenberg J, et al. Randomized trial of efficacy of Spf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994 344 : 1175 1181.
8. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004 364 : 1411 1420.
9. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001 357 : 1471 1477.
10. Moorthy V, Reed Z Smith PG. Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine 2007 25 : 5115 5123.
11. Bejon P, Mwacharo J, Kai O, et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006 1 : e29.
12. Rhodes PH, Halloran ME Longini IM. Counting Process Models for Infectious Disease Data: Distinguishing Exposure to Infection from Susceptibility. J Roy Stat Soc Ser B (Stat Method) 1996 58 : 751 762.
13. Greenwood B. Malaria vaccines evaluation and implementation. Acta Trop 2005 95 : 298 304.
14. Marsh K Snow RW. Malaria transmission and morbidity. Parassitologia 1999 41 : 241 246.
15. O'Meara WP, Mwangi T, Williams T, McKenzie FE, Snow R Marsh K. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 2008 79 : 185 191.
16. Maire N, Tediosi F, Ross A Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg 2006 75 (2 Suppl. 111 118.
17. Rogers WO, Atuguba F, Oduro AR, Hodgson A Koram KA. Clinical case definitions and malaria vaccine efficacy. J Infect Dis 2006 193 : 467 473.
18. Mwangi TW, Ross A, Snow RW Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 2005 191 : 1932 1939.
19. Gwer S, Newton CR Berkley JA. Over-diagnosis and co-morbidity of severe malaria in African children: a guide for clinicians. Am J Trop Med Hyg 2007 77 (6 Suppl. 6 13.
20. Bejon P, Berkley JA, Mwangi T, et al. Defining childhood severe falciparum malaria for intervention studies. PLoS Med 2007 4 : e251.
21. O'Meara WP, Hall BF McKenzie FE. Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. Malar J 2007 6 : 36.
22. Calis JC, Phiri KS, Faragher EB, et al. Severe anemia in Malawian children. N Engl J Med 2008 358 : 888 899.
23. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004 10 : 143 145.
24. Smith T, Schellenberg JA Hayes R. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 1994 13 : 2345 2358. (Pubitemid 24354857)
25. Vounatsou P, Smith T, Kitua AY, Alonso PL Tanner M. Apparent tolerance of Plasmodium falciparum in infants in a highly endemic area. Parasitology 2000 120 : 1 9.
26. Dicko A, Mantel C, Kouriba B, et al. Season, fever prevalence and pyrogenic threshold for malaria disease definition in an endemic area of Mali. Trop Med Int Health 2005 10 : 550 556.
27. McGuinness D, Koram K, Bennett S, Wagner G, Nkrumah F Riley E. Clinical case definitions for malaria: clinical malaria associated with very low parasite densities in African infants. Trans R Soc Trop Med Hyg 1998 92 : 527 531.
28. Rogier C, Commenges D Trape JF. Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. Am J Trop Med Hyg 1996 54 : 613 619.
29. Smith TA. Measures of clinical malaria in field trials of interventions against Plasmodium falciparum. Malar J 2007 6 : 53.
30. WHO. Guidelines for the Evaluation of Plasmodium falciparum Vaccines in Populations Exposed to Natural Infection. World Health Organisation, Geneva, 1997 TDR Report.
31. Lachenbruch PA. Sensitivity, specificity, and vaccine efficacy. Control Clin Trials 1998 19 : 569 574.
32. Langhorne J, Ndungu FM, Sponaas AM Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008 9 : 725 732.
33. Mwangi TW, Fegan G, Williams TN, Kinyanjui SM, Snow RW Marsh K. Evidence for over-dispersion in the distribution of clinical malaria episodes in children. PLoS ONE 2008 3 : e2196.
34. Smith DL, Dushoff J McKenzie FE. The risk of a mosquito-borne infection in a heterogeneous environment. PLoS Biol 2004 2 : e368.
35. Mackinnon MJ, Mwangi TW, Snow RW, Marsh K Williams TN. Heritability of malaria in Africa. Plos Med 2005 2 : 1253 1259.
36. Smith T, Charlwood JD, Kitua AY, et al. Relationships of malaria morbidity with exposure to Plasmodium falciparum in young children in a highly endemic area. Am J Trop Med Hyg 1998 59 : 252 257.
37. Halloran ME, Longini IM Jr. Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev 1999 21 : 73 88.
38. Durham LK, Longini IM Jr., Halloran ME, Clemens JD, Nizam A Rao M. Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. Am J Epidemiol 1998 147 : 948 959. (Pubitemid 28244166)
39. Halloran ME, Longini IM Struchiner CJ. Estimability and interpretation of vaccine efficacy using frailty mixing models. Am J Epidemiol 1996 144 : 83 97.
40. Valim C, Mezzetti M, Maguire J, Urdaneta M Wypij D. Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection. Philos Transact A Math Phys Eng Sci 2008 366 : 2347 2360.
41. Kester KE, Cummings JF, Ockenhouse CF, et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 2008 26 : 2191 2202.
42. Reyburn H, Mbatia R, Drakeley C, et al. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 2005 293 : 1461 1470.
43. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997 349 : 1650 1654.
44. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007 4 : e309.
45. Graves PM, Osgood DE, Thomson MC, et al. Effectiveness of malaria control during changing climate conditions in Eritrea, 1998-2003. Trop Med Int Health 2008 13 : 218 228.
46. Killeen GF, Tami A, Kihonda J, et al. Cost-sharing strategies combining targeted public subsidies with private-sector delivery achieve high bednet coverage and reduced malaria transmission in Kilombero Valley, southern Tanzania. BMC Infect Dis 2007 7 : 121.
47. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007 6 : 151.
48. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P Hill AV. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008 78 : 878 883.
49. Cheng Q, Lawrence G, Reed C, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997 57 : 495 500.